Clicks annual results show group turnover passing R50bn for the first time, as the health and beauty retailer returned R976m in cashback rewards to loyalty members. Turnover rose 5.4% to R50.4bn in the year to end-August, or about R138m a day. Loyalty and discounts amid cost pressures Clicks ClubCard had 13.1 million active members, who accounted for more than four-fifths…
Tag: Single Exit Price
-
Medicine Price Increase Adds R1bn to Scheme Costs
An extraordinary medicine price increase could add R1bn to medical schemes’ costs in 2027, after schemes submitted their budgets. The Health Department announced the additional 2.88% single exit price (SEP) adjustment on 30 September, effective from 1 October. It cited cost pressures for pharmaceutical manufacturers, including geopolitical tensions. The adjustment follows an earlier 1.47% increase in 2026. Although annual increases…
-
Pharmaceutical Policy Must Balance Price With Supply
South Africa’s pharmaceutical policy must protect patients through affordable medicines. Still, it cannot pursue the lowest possible price at the cost of the local industry that keeps those medicines flowing, an industry expert argues. Writing from years in the sector and doctoral research on generic pricing, the author poses a harder question. What happens when the drive for cheap medicines…
-
Single Exit Price to Rise 2.88% as Industry Warns of Shortages
The single exit price for medicines will rise 2.88% from October. The industry warns rising input costs are straining medicine supply. The single exit price (SEP) of medicines and scheduled substances will rise 2.88% from 1 October. This is the second adjustment this year. South Africa’s pharmaceutical industry warns that rising input costs are squeezing medicine supply and triggering shortages.…
-
Local Pharmaceutical Manufacturing Needs Urgent Support
An industry group has warned that South Africa’s emphasis on securing the lowest possible prices for medicine is excluding local pharmaceutical companies from important state contracts. This issue highlights the challenges faced by local pharmaceutical manufacturing. In particular, they struggle to remain competitive in the market. Pharmaceuticals Made in South Africa (Pharmisa) told Parliament that the Health Department’s procurement policies…